CHNQD-01255

BIOLOGICAL ACT

Description

In Vitro

In Vivo

Administration:

Animal Model:

Administration:

Dosage:

Result:

MedChemExpress

Please store the product un Analysis.	der the recommended conditions in the Certificate of	Proteins						
CHNQD-01255 is an orall	y active Arf-GEFs inhibitor with potent anti-hepatocellular carcinoma (HCC) efficacy $^{[1]}$.							
MCE has not independer	pproximately, 72 h) inhibits HepG2 and BEL-7402 cell proliferation ^[1] . htly confirmed the accuracy of these methods. They are for reference only. HNQD-01255 (0-1 μM approximately, 72 h) inhibits HepG2 and BEL-7402 cell proliferation ^[1] .							
Cell Line:	Cell Line: HepG2, BEL-7402 cell							
Concentration:	Concentration: 0-1 µM approximately							
Incubation Time:	72 h							
Result:	Inhibited cell proliferation with an IC_{50} value of 0.1 μM (HepG2) and 0.07 μM (BEL-7402).							
CHNQD-01255 exhibits a mice ^[1] .	/kg, p.o.) inhibits tumor growth in HepG2 tumor-bearing xenograft mice ^[1] . high safety profile with MTD values exceeding 750 and 100 mg/kg for p.o. and i.p. administration ntly confirmed the accuracy of these methods. They are for reference only.	s in						
Animal Model:	HepG2 tumor-bearing xenograft mice ^[1]	ift mice ^[1]						
Dosage:	5, 15, and 45 mg/kg							

Oral adminstration (p.o.), every day for 21 consecutive days.

Intraperitoneal injection (i.p.), every day for 21 consecutive days.

(TGI %) value of 61.0% at 45 mg/kg.

1 and 9 mg/kg

HepG2 tumor-bearing xenograft mice^[1]

Resulted in dramatically delayed tumor progression, with a tumor growth inhibition rate

Product Data Sheet

Result:	Inhibited the tu	imor growt	h with the TGI va	llues of 36.6 and	48.3%, respe	
Animal Model:	Mice (Pharmacokinetic assay) ^[1]					
Dosage:	45 mg/kg p.o., 10 mg/kg i.v.					
Administration:	Oral adminstration (p.o.) or intravenous injection (i.v.)					
Result:	Pharmacokinetic profile of CHNQD-01255.					
	dose (mg/kg)	T _{1/2} (h)	C _{max} (ng/mL)	Cl (mL/h/kg)	F (%)	
	45 (p.o.)	7.35	20.26	598245.37	2.26	
	10 (i.v.)		2060.78			

REFERENCES

[1]. Yao-Yao Jiang, et al. Design and Characterization of a Natural Arf-GEFs Inhibitor Prodrug CHNQD-01255 with Potent Anti-Hepatocellular Carcinoma Efficacy In Vivo. J Med Chem. 2022 Sep 22;65(18):11970-11984.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA